|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feng RM, Zong YN, Cao SM and Xu RH:
Current cancer situation in China: Good or bad news from the 2018
Global Cancer Statistics? Cancer Commun (Lond). 39:222019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hausman DM: What Is Cancer? Perspect Biol
Med. 62:778–784. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vinay DS, Ryan EP, Pawelec G, Talib WH,
Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, et
al: Immune evasion in cancer: Mechanistic basis and therapeutic
strategies. Semin Cancer Biol. 35 (Suppl):S185–S198. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qin A, Coffey DG, Warren EH and Ramnath N:
Mechanisms of immune evasion and current status of checkpoint
inhibitors in non-small cell lung cancer. Cancer Med. 5:2567–2578.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q,
Kasinath V, Ichimura T, Banouni N, Dai L, Li X, et al: Direct tumor
killing and immunotherapy through Anti-SerpinB9 therapy. Cell.
183:1219–1233.e18. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lucas A, Yaron JR, Zhang L and Ambadapadi
S: Overview of serpins and their roles in biological systems.
Methods Mol Biol. 1826:1–7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh P and Jairajpuri MA: Structure
function analysis of serpin super-family: ‘a computational
approach’. Protein Pept Lett. 21:714–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Law RH, Zhang Q, McGowan S, Buckle AM,
Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI
and Whisstock JC: An overview of the serpin superfamily. Genome
Biol. 7:2162006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Gent D, Sharp P, Morgan K and
Kalsheker N: Serpins: Structure, function and molecular evolution.
Int J Biochem Cell Biol. 35:1536–1547. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gatto M, Iaccarino L, Ghirardello A, Bassi
N, Pontisso P, Punzi L, Shoenfeld Y and Doria A: Serpins, immunity
and autoimmunity: Old molecules, new functions. Clin Rev Allergy
Immunol. 45:267–280. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marijanovic EM, Fodor J, Riley BT,
Porebski BT, Costa M, Kass I, Hoke DE, McGowan S and Buckle AM:
Reactive centre loop dynamics and serpin specificity. Sci Rep.
9:38702019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olson ST and Gettins PG: Regulation of
proteases by protein inhibitors of the serpin superfamily. Prog Mol
Biol Transl Sci. 99:185–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rashid Q, Kapil C, Singh P, Kumari V and
Jairajpuri MA: Understanding the specificity of serpin-protease
complexes through interface analysis. J Biomol Struct Dyn.
33:1352–1362. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaiserman D and Bird PI: Control of
granzymes by serpins. Cell Death Differ. 17:586–595. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pike RN, Bottomley SP, Irving JA, Bird PI
and Whisstock JC: Serpins: Finely balanced conformational traps.
Iubmb Life. 54:1–7. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huntington JA, Read RJ and Carrell RW:
Structure of a serpin-protease complex shows inhibition by
deformation. Nature. 407:923–926. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huntington JA: Serpin structure, function
and dysfunction. J Thromb Haemost. 9 (Suppl 1):S26–S34. 2011.
View Article : Google Scholar
|
|
19
|
Zheng D, Chen H, Davids J, Bryant M and
Lucas A: Serpins for diagnosis and therapy in cancer. Cardiovasc
Hematol Disord Drug Targets. 13:123–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Utaijaratrasmi P, Vaeteewoottacharn K,
Tsunematsu T, Jamjantra P, Wongkham S, Pairojkul C, Khuntikeo N,
Ishimaru N, Sirivatanauksorn Y, Pongpaibul A, et al: The
microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated
fibroblasts promotes migration of cancer cells. Mol Cancer.
17:102018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gettins PG: Serpin structure, mechanism,
and function. Chem Rev. 102:4751–4804. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pontisso P: Role of SERPINB3 in
hepatocellular carcinoma. Ann Hepatol. 13:722–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hong H, Zhou T, Fang S, Jia M, Xu Z, Dai
Z, Li C, Li S, Li L, Zhang T, et al: Pigment epithelium-derived
factor (PEDF) inhibits breast cancer metastasis by down-regulating
fibronectin. Breast Cancer Res Treat. 148:61–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou D, Cheng SQ, Ji HF, Wang JS, Xu HT,
Zhang GQ and Pang D: Evaluation of protein pigment
epithelium-derived factor (PEDF) and microvessel density (MVD) as
prognostic indicators in breast cancer. J Cancer Res Clin Oncol.
136:1719–1727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Silverman GA, Whisstock JC, Askew DJ, Pak
SC, Luke CJ, Cataltepe S, Irving JA and Bird PI: Human clade B
serpins (ov-serpins) belong to a cohort of evolutionarily dispersed
intracellular proteinase inhibitor clades that protect cells from
promiscuous proteolysis. Cell Mol Life Sci. 61:301–325. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Izuhara K, Ohta S, Kanaji S, Shiraishi H
and Arima K: Recent progress in understanding the diversity of the
human ov-serpin/clade B serpin family. Cell Mol Life Sci.
65:2541–2553. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eyre HJ, Sun J, Sutherland GR and Bird P:
Chromosomal mapping of the gene (PI9) encoding the intracellular
serpin proteinase inhibitor 9 to 6p25 by fluorescence in situ
hybridization. Genomics. 37:406–408. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun J, Bird CH, Sutton V, McDonald L,
Coughlin PB, De Jong TA, Trapani JA and Bird PI: A cytosolic
granzyme B inhibitor related to the viral apoptotic regulator
cytokine response modifier A is present in cytotoxic lymphocytes. J
Biol Chem. 271:27802–27809. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sprecher CA, Morgenstern KA, Mathewes S,
Dahlen JR, Schrader SK, Foster DC and Kisiel W: Molecular cloning,
expression, and partial characterization of two novel members of
the ovalbumin family of serine proteinase inhibitors. J Biol Chem.
270:29854–29861. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bird CH, Sutton VR, Sun J, Hirst CE, Novak
A, Kumar S, Trapani JA and Bird PI: Selective regulation of
apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9
protects against granzyme B-mediated apoptosis without perturbing
the Fas cell death pathway. Mol Cell Biol. 18:6387–6398. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Trapani JA and Sutton VR: Granzyme B:
Pro-apoptotic, antiviral and antitumor functions. Curr Opin
Immunol. 15:533–543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang M, Park SM, Wang Y, Shah R, Liu N,
Murmann AE, Wang CR, Peter ME and Ashton-Rickardt PG: Serine
protease inhibitor 6 protects cytotoxic T cells from self-inflicted
injury by ensuring the integrity of cytotoxic granules. Immunity.
24:451–461. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ansari AW, Temblay JN, Alyahya SH and
Ashton-Rickardt PG: Serine protease inhibitor 6 protects iNKT cells
from self-inflicted damage. J Immunol. 185:877–883. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Andrew KA, Simkins HM, Witzel S, Perret R,
Hudson J, Hermans IF, Ritchie DS, Yang J and Ronchese F: Dendritic
cells treated with lipopolysaccharide up-regulate serine protease
inhibitor 6 and remain sensitive to killing by cytotoxic T
lymphocytes in vivo. J Immunol. 181:8356–8362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lovo E, Zhang M, Wang L and
Ashton-Rickardt PG: Serine protease inhibitor 6 is required to
protect dendritic cells from the kiss of death. J Immunol.
188:1057–1063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mangan MS, Vega-Ramos J, Joeckel LT,
Mitchell AJ, Rizzitelli A, Roediger B, Kaiserman D, Weninger WW,
Villadangos JA and Bird PI: Serpinb9 is a marker of antigen
cross-presenting dendritic cells. Mol Immunol. 82:50–56. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Classen CF, Bird PI and Debatin KM:
Modulation of the granzyme B inhibitor proteinase inhibitor 9
(PI-9) by activation of lymphocytes and monocytes in vitro and by
Epstein-Barr virus and bacterial infection. Clin Exp Immunol.
143:534–542. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bladergroen BA, Strik MC, Bovenschen N,
van Berkum O, Scheffer GL, Meijer CJ, Hack CE and Kummer JA: The
granzyme B inhibitor, protease inhibitor 9, is mainly expressed by
dendritic cells and at immune-privileged sites. J Immunol.
166:3218–3225. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Young JL, Sukhova GK, Foster D, Kisiel W,
Libby P and Schönbeck U: The serpin proteinase inhibitor 9 is an
endogenous inhibitor of interleukin 1beta-converting enzyme
(caspase-1) activity in human vascular smooth muscle cells. J Exp
Med. 191:1535–1544. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rowshani AT, Florquin S, Bemelman F,
Kummer JA, Hack CE and Ten BI: Hyperexpression of the granzyme B
inhibitor PI-9 in human renal allografts: A potential mechanism for
stable renal function in patients with subclinical rejection.
Kidney Int. 66:1417–1422. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rowshani AT, Strik MC, Molenaar R, Yong
SL, Wolbink AM, Bemelman FJ, Hack CE and Ten BI: The granzyme B
inhibitor SERPINB9 (protease inhibitor 9) circulates in blood and
increases on primary cytomegalovirus infection after renal
transplantation. J Infect Dis. 192:1908–1911. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lau A, Khan K, Pavlosky A, Yin Z, Huang X,
Haig A, Liu W, Singh B, Zhang ZX and Jevnikar AM: Serine protease
inhibitor-6 inhibits granzyme B-mediated injury of renal tubular
cells and promotes renal allograft survival. Transplantation.
98:402–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sanad EF, Hamdy NM, El-Etriby AK, Sebak SA
and El-Mesallamy HO: Peripheral leucocytes and tissue gene
expression of granzyme B/perforin system and serpinB9: Impact on
inflammation and insulin resistance in coronary atherosclerosis.
Diabetes Res Clin Pract. 131:132–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Heutinck KM, Kassies J, Florquin S, Ten
BI, Hamann J and Rowshani AT: SerpinB9 expression in human renal
tubular epithelial cells is induced by triggering of the viral
dsRNA sensors TLR3, MDA5 and RIG-I. Nephrol Dial Transplant.
27:2746–2754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
van der Burgh R, Meeldijk J, Jongeneel L,
Frenkel J, Bovenschen N, van Gijn M and Boes M: Reduced
serpinB9-mediated caspase-1 inhibition can contribute to
autoinflammatory disease. Oncotarget. 7:19265–19271. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kaartokallio T, Cervera A, Kyllönen A,
Laivuori K, Kere J and Laivuori H: Gene expression profiling of
pre-eclamptic placentae by RNA sequencing. Sci Rep. 5:141072015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ten BR, Meijer CJ, Dukers DF, Kummer JA,
Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ and Oudejans JJ:
Expression levels of apoptosis-related proteins predict clinical
outcome in anaplastic large cell lymphoma. Blood. 99:4540–4546.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pohjanen VM, Kokkonen TS, Arvonen M,
Augustin MA, Patankar M, Turunen S, Vähäsalo P and Karttunen TJ:
Decreased expression of protease inhibitor 9, a granzyme B
inhibitor, in celiac disease: A potential mechanism in enterocyte
destruction and villous atrophy. Int J Immunopathol Pharmacol.
26:897–905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vycital O, Pitule P, Hosek P, Kriz T,
Treska V and Liska V: Expression of serpin B9 as a prognostic
factor of colorectal cancer. Anticancer Res. 39:6063–6066. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
McCorkle JR, Leonard MK, Kraner SD,
Blalock EM, Ma D, Zimmer SG and Kaetzel DM: The metastasis
suppressor NME1 regulates expression of genes linked to metastasis
and patient outcome in melanoma and breast carcinoma. Cancer
Genomics Proteomics. 11:175–194. 2014.PubMed/NCBI
|
|
52
|
Ferreri AJ, Govi S, Pileri SA and Savage
KJ: Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol
Hematol. 85:206–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bots M, Offringa R and Medema JP: Does the
serpin PI-9 protect tumor cells? Blood. 107:4974–4975, 4975. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Luo H and Ma C: Identification of
prognostic genes in uveal melanoma microenvironment. PLoS One.
15:e2422632020. View Article : Google Scholar
|
|
55
|
Zhou B, Chen E, Chen J, Zhang J, Zhang N
and Chen Z: Overexpression of proteinase inhibitor 9 is associated
with poor prognosis in human hepatocellular carcinoma and with
proliferation and apoptosis in HepG2 cells in vitro. Int J Clin Exp
Pathol. 12:3719–3727. 2019.PubMed/NCBI
|
|
56
|
Schiffer S, Hansen HP, Hehmann-Titt G,
Huhn M, Fischer R, Barth S and Thepen T: Efficacy of an adapted
granzyme B-based anti-CD30 cytolytic fusion protein against
PI-9-positive classical Hodgkin lymphoma cells in a murine model.
Blood Cancer J. 3:e1062013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Peters FS, Peeters A, van den Bosch T,
Mooyaart AL, van de Wetering J, Betjes M, Baan CC and Boer K:
Disrupted regulation of serpinB9 in circulating T cells is
associated with an increased risk for post-transplant skin cancer.
Clin Exp Immunol. 197:341–351. 2019.PubMed/NCBI
|
|
58
|
Vycital O, Dubova M, Palek R, Hosek P,
Branzovsky J, Treska V, Daum O and Liska V: The impact of immune
interaction on the metastatic infiltration of colorectal carcinoma
to lymph nodes. Anticancer Res. 38:4159–4167. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Repetto O, De Re V, De Paoli A, Belluco C,
Alessandrini L, Canzonieri V and Cannizzaro R: Identification of
protein clusters predictive of tumor response in rectal cancer
patients receiving neoadjuvant chemo-radiotherapy. Oncotarget.
8:28328–28341. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lauricella M, Carlisi D, Giuliano M,
Calvaruso G, Cernigliaro C, Vento R and D'Anneo A: The analysis of
estrogen receptor-α positive breast cancer stem-like cells unveils
a high expression of the serpin proteinase inhibitor PI-9: Possible
regulatory mechanisms. Int J Oncol. 49:352–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kuo LC, Cheng LC, Lee CH, Lin CJ, Chen PY
and Li LA: Estrogen and cigarette sidestream smoke particulate
matter exhibit ERα-dependent tumor-promoting effects in lung
adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol.
313:L477–L490. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Rousalova I, Krepela E, Prochazka J,
Cermak J and Benkova K: Expression of proteinase
inhibitor-9/serpinB9 in non-small cell lung carcinoma cells and
tissues. Int J Oncol. 36:275–283. 2010.PubMed/NCBI
|
|
63
|
Tanaka K, Harashima N, Niiya F, Miyagi Y,
Hida N, Ochi M, Imai N, Harada M, Itoh K and Shichijo S: Serine
proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes
of epithelial cancer patients. Jpn J Cancer Res. 93:198–208. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kannan-Thulasiraman P and Shapiro DJ:
Modulators of inflammation use nuclear factor-kappa B and activator
protein-1 sites to induce the caspase-1 and granzyme B inhibitor,
proteinase inhibitor 9. J Biol Chem. 277:41230–41239. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Soriano C, Mukaro V, Hodge G, Ahern J,
Holmes M, Jersmann H, Moffat D, Meredith D, Jurisevic C, Reynolds
PN and Hodge S: Increased proteinase inhibitor-9 (PI-9) and reduced
granzyme B in lung cancer: Mechanism for immune evasion? Lung
Cancer. 77:38–45. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ko YH, Park S, Jin H, Woo H, Lee H, Park C
and Kim K: Granzyme B leakage-induced apoptosis is a crucial
mechanism of cell death in nasal-type NK/T-cell lymphoma. Lab
Invest. 87:241–250. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kummer JA, Micheau O, Schneider P,
Bovenschen N, Broekhuizen R, Quadir R, Strik MC, Hack CE and
Tschopp J: Ectopic expression of the serine protease inhibitor PI9
modulates death receptor-mediated apoptosis. Cell Death Differ.
14:1486–1496. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bots M, Kolfschoten IG, Bres SA, Rademaker
MT, de Roo GM, Krüse M, Franken KL, Hahne M, Froelich CJ, Melief
CJ, et al: SPI-CI and SPI-6 cooperate in the protection from
effector cell-mediated cytotoxicity. Blood. 105:1153–1161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lakshmi NB, Eshvendar RK, Shantikumar S
and Ramakrishna S: Immune system: A double-edged sword in cancer.
Inflamm Res. 62:823–834. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Riley RS, June CH, Langer R and Mitchell
MJ: Delivery technologies for cancer immunotherapy. Nat Rev Drug
Discov. 18:175–196. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Helmy KY, Patel SA, Nahas GR and Rameshwar
P: Cancer immunotherapy: Accomplishments to date and future
promise. Ther Deliv. 4:1307–1320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Bladergroen BA, Meijer CJ, Ten BR, Hack
CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum
O and Kummer JA: Expression of the granzyme B inhibitor, protease
inhibitor 9, by tumor cells in patients with non-Hodgkin and
Hodgkin lymphoma: A novel protective mechanism for tumor cells to
circumvent the immune system? Blood. 99:232–237. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Choi PJ and Mitchison TJ: Quantitative
analysis of resistance to natural killer attacks reveals stepwise
killing kinetics. Integr Biol (Camb). 6:1153–1161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Jiang X, Ellison SJ, Alarid ET and Shapiro
DJ: Interplay between the levels of estrogen and estrogen receptor
controls the level of the granzyme inhibitor, proteinase inhibitor
9 and susceptibility to immune surveillance by natural killer
cells. Oncogene. 26:4106–4114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jiang X, Patterson NM, Ling Y, Xie J,
Helferich WG and Shapiro DJ: Low concentrations of the soy
phytoestrogen genistein induce proteinase inhibitor 9 and block
killing of breast cancer cells by immune cells. Endocrinology.
149:5366–5373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Muris JJ, Meijer CJ, Cillessen SA, Vos W,
Kummer JA, Bladergroen BA, Bogman MJ, MacKenzie MA, Jiwa NM,
Siegenbeek VHL, et al: Prognostic significance of activated
cytotoxic T-lymphocytes in primary nodal diffuse large B-cell
lymphomas. Leukemia. 18:589–596. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tang CH, Sue YM, Hsieh WT, Wang YH and
Wang CC: Increased risk of cutaneous squamous cell carcinoma in
organ transplant recipients and patients on chronic dialysis: A
cancer registry-based study in taiwan. Acta Derm Venereol.
99:1275–1281. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Vermeulen JF, van Hecke W, Spliet WG,
Villacorta HJ, Fisch P, Broekhuizen R and Bovenschen N: Pediatric
primitive neuroectodermal tumors of the central nervous system
differentially express granzyme inhibitors. PLoS One.
11:e1514652016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Buzza MS, Hosking P and Bird PI: The
granzyme B inhibitor, PI-9, is differentially expressed during
placental development and up-regulated in hydatidiform moles.
Placenta. 27:62–69. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ray M, Hostetter DR, Loeb CR, Simko J and
Craik CS: Inhibition of Granzyme B by PI-9 protects prostate cancer
cells from apoptosis. Prostate. 72:846–855. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Jiang X, Orr BA, Kranz DM and Shapiro DJ:
Estrogen induction of the granzyme B inhibitor, proteinase
inhibitor 9, protects cells against apoptosis mediated by cytotoxic
T lymphocytes and natural killer cells. Endocrinology.
147:1419–1426. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Bossard C, Belhadj K, Reyes F,
Martin-Garcia N, Berger F, Kummer JA, Brière J, Baglin AC, Cheze S,
Bosq J, et al: Expression of the granzyme B inhibitor PI9 predicts
outcome in nasal NK/T-cell lymphoma: Results of a Western series of
48 patients treated with first-line polychemotherapy within the
Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood.
109:2183–2189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Tse E and Kwong YL: NK/T-cell lymphomas.
Best Pract Res Clin Haematol. 32:253–261. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zeeshan R and Mutahir Z: Cancer
metastasis-tricks of the trade. Bosn J Basic Med Sci. 17:172–182.
2017.PubMed/NCBI
|
|
85
|
Milette S, Hashimoto M, Perrino S, Qi S,
Chen M, Ham B, Wang N, Istomine R, Lowy AM, Piccirillo CA and Brodt
P: Sexual dimorphism and the role of estrogen in the immune
microenvironment of liver metastases. Nat Commun. 10:57452019.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Selicharova I, Sanda M, Mladkova J, Ohri
SS, Vashishta A, Fusek M, Jiracek J and Vetvicka V: 2-DE analysis
of breast cancer cell lines 1833 and 4175 with distinct metastatic
organ-specific potentials: Comparison with parental cell line
MDA-MB-231. Oncol Rep. 19:1237–1244. 2008.PubMed/NCBI
|
|
87
|
Vermijlen D, Luo D, Froelich CJ, Medema
JP, Kummer JA, Willems E, Braet F and Wisse E: Hepatic natural
killer cells exclusively kill splenic/blood natural
killer-resistant tumor cells by the perforin/granzyme pathway. J
Leukoc Biol. 72:668–676. 2002.PubMed/NCBI
|
|
88
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sullivan EM, Jeha S, Kang G, Cheng C,
Rooney B, Holladay M, Bari R, Schell S, Tuggle M, Pui CH and Leung
W: NK cell genotype and phenotype at diagnosis of acute
lymphoblastic leukemia correlate with postinduction residual
disease. Clin Cancer Res. 20:5986–5994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Cunningham TD, Jiang X and Shapiro DJ:
Expression of high levels of human proteinase inhibitor 9 blocks
both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity.
Cell Immunol. 245:32–41. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Baskar R, Lee KA, Yeo R and Yeoh KW:
Cancer and radiation therapy: Current advances and future
directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Chen J, Cao Y, Markelc B, Kaeppler J,
Vermeer JA and Muschel RJ: Type I IFN protects cancer cells from
CD8+ T cell-mediated cytotoxicity after radiation. J
Clin Invest. 129:4224–4238. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ilienko IM, Golyarnik NA, Lyaskivska OV,
Belayev OA and Bazyka DA: Expression of biological markers induced
by ionizing radiation at the late period after exposure in a wide
range of doses. Probl Radiac Med Radiobiol. 23:331–350. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Medema JP, de Jong J, Peltenburg LT,
Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP,
Melief CJ and Offringa R: Blockade of the granzyme B/perforin
pathway through overexpression of the serine protease inhibitor
PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.
Proc Natl Acad Sci USA. 98:11515–11520. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Melo AM, Conroy MJ, Foley EK, Dockry É,
Breen EP, Reynolds JV, Lysaght J and Doherty DG: CD1d expression
and invariant natural killer T-cell numbers are reduced in patients
with upper gastrointestinal cancers and are further impaired by
commonly used chemotherapies. Cancer Immunol Immunother.
69:969–982. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Senju S, Hirata S, Motomura Y, Fukuma D,
Matsunaga Y, Fukushima S, Matsuyoshi H and Nishimura Y: Pluripotent
stem cells as source of dendritic cells for immune therapy. Int J
Hematol. 91:392–400. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Fukuma D, Matsuyoshi H, Hirata S, Kurisaki
A, Motomura Y, Yoshitake Y, Shinohara M, Nishimura Y and Senju S:
Cancer prevention with semi-allogeneic ES cell-derived dendritic
cells. Biochem Biophys Res Commun. 335:5–13. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kuşoğlu A and Biray AÇ: Cancer stem cells:
A brief review of the current status. Gene. 681:80–85. 2019.
View Article : Google Scholar
|
|
99
|
Erkisa M, Karakas D and Ulukaya E: Cancer
stem cells: Root of the evil. Crit Rev Oncog. 24:69–87. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
El HN, Heathcote D, Moore R, Yang S, Azzi
J, Mfarrej B, Atkinson M, Sayegh MH, Lee JS, Ashton-Rickardt PG and
Abdi R: Mesenchymal stem cells express serine protease inhibitor to
evade the host immune response. Blood. 117:1176–1183. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Abdullah Z, Saric T, Kashkar H, Baschuk N,
Yazdanpanah B, Fleischmann BK, Hescheler J, Krönke M and Utermöhlen
O: Serpin-6 expression protects embryonic stem cells from lysis by
antigen-specific CTL. J Immunol. 178:3390–3399. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lourenco S, Teixeira VH, Kalber T, Jose
RJ, Floto RA and Janes SM: Macrophage migration inhibitory
factor-CXCR4 is the dominant chemotactic axis in human mesenchymal
stem cell recruitment to tumors. J Immunol. 194:3463–3474. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hjelmeland AB, Wu Q, Heddleston JM,
Choudhary GS, MacSwords J, Lathia JD, McLendon R, Lindner D, Sloan
A and Rich JN: Acidic stress promotes a glioma stem cell phenotype.
Cell Death Differ. 18:829–840. 2011. View Article : Google Scholar : PubMed/NCBI
|
